{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:43:18Z","timestamp":1793313798083,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jaad.2021.06.017","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T11:34:15Z","timestamp":1623411255000},"page":"628-636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Management of inadequate response and adverse effects to dupilumab in atopic dermatitis"],"prefix":"10.1016","volume":"86","author":[{"given":"Shanthi","family":"Narla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2021.06.017_bib1","first-page":"e7565","article-title":"Dupilumab for Atopic dermatitis: the silver bullet we have been searching for?","volume":"12","author":"Tameez Ud Din","year":"2020","journal-title":"Cureus"},{"issue":"24","key":"10.1016\/j.jaad.2021.06.017_bib2","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.017_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0536.2006.00927.x","article-title":"The aetiology of eyelid dermatitis: a 10-year retrospective analysis","volume":"55","author":"Amin","year":"2006","journal-title":"Contact dermatitis"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.017_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1365-2133.2008.08790.x","article-title":"Periorbital dermatitis\u2013A recalcitrant disease: causes and differential diagnoses","volume":"159","author":"Feser","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0536.2009.01669.x","article-title":"The epidemiology of hand eczema in the general population: prevalence and main findings","volume":"62","author":"Thyssen","year":"2010","journal-title":"Contact Dermatitis"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/DER.0000000000000371","article-title":"Genital allergic contact dermatitis","volume":"29","author":"Yale","year":"2018","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.017_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2310\/6620.2010.10053","article-title":"Positive patch-test reactions to iodopropynyl butylcarbamate: retrospective analysis of North American contact dermatitis group data, from 1998 to 2008","volume":"21","author":"Warshaw","year":"2010","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","article-title":"Management of difficult-to-treat atopic dermatitis","volume":"1","author":"Arkwright","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.jaad.2021.06.017_bib13","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/sj.jid.5701018","article-title":"Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study","volume":"127","author":"Joly","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.anai.2017.09.061","article-title":"Clinical approach to the patient with refractory atopic dermatitis","volume":"120","author":"Izadi","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2021.06.017_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/CCID.S185357","article-title":"A diagnostic checklist for generalized dermatitis","volume":"11","author":"Nedorost","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.017_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.rdc.2011.09.003","article-title":"Neoplastic\/paraneoplastic dermatitis, fasciitis, and panniculitis","volume":"37","author":"Shah","year":"2011","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2021.06.017_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.06.017_bib18","article-title":"Mycosis fungoides unmasked by dupilumab treatment in a patient with a history of atopic dermatitis","author":"Ayasse","year":"2020","journal-title":"Dermatitis"},{"issue":"9","key":"10.1016\/j.jaad.2021.06.017_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2040622318773686","article-title":"Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy","volume":"9","author":"Ari\u00ebns","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"10.1016\/j.jaad.2021.06.017_bib20","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","article-title":"A review of dupilumab in the treatment of atopic diseases","volume":"15","author":"Thibodeaux","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2021.06.017_bib22","article-title":"Treatment of patients with atopic\u00a0dermatitis with weekly dupilumab dosing: a single institutional retrospective medical record review and survey","author":"Gao","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"10086","key":"10.1016\/j.jaad.2021.06.017_bib24","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000512456","article-title":"A short cycle of narrow-band UVB phototherapy in the early phase of dupilumab therapy can provide a quicker improvement of severe atopic dermatitis","volume":"237","author":"Rossi","year":"2021","journal-title":"Dermatology"},{"issue":"4S","key":"10.1016\/j.jaad.2021.06.017_bib27","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","article-title":"Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines","volume":"139","author":"Eichenfield","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2021.06.017_bib28","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","author":"Murphy","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.06.017_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Zhu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.06.017_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaad.2019.03.020","article-title":"Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis","volume":"81","author":"Stout","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaad.2019.09.028","article-title":"The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review","volume":"82","author":"Raffi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.06.017_bib33","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2015.141","article-title":"Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1\/Th17 Pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.06.017_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3346\/jkms.2011.26.9.1231","article-title":"Clinical and immunological responses in ocular demodecosis","volume":"26","author":"Kim","year":"2011","journal-title":"J Korean Med Sci"},{"issue":"10","key":"10.1016\/j.jaad.2021.06.017_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","article-title":"A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses","volume":"72","author":"Hajar","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.017_bib38","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.017_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/DER.0000000000000509","article-title":"Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab","volume":"30","author":"Stout","year":"2019","journal-title":"Dermatitis"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/ced.14207","article-title":"Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab","volume":"45","author":"Ferrucci","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.017_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"issue":"10","key":"10.1016\/j.jaad.2021.06.017_bib43","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.017_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2020.04.015","article-title":"Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6\/PPAR\u03b3 signaling pathway","volume":"18","author":"Jun","year":"2020","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib45","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1038\/s41598-018-30002-x","article-title":"Context-dependent regulation of conjunctival goblet cell function by allergic mediators","volume":"8","author":"Garc\u00eda-Posadas","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijwd.2019.08.007","article-title":"Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD)","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.06.017_bib48","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report","volume":"5","author":"Zirwas","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2021.06.017_bib50","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2013International eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijwd.2019.10.001","article-title":"Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)'","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.017_bib53","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of\u00a0inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2021.06.017_bib55","doi-asserted-by":"crossref","first-page":"420","DOI":"10.18176\/jiaci.0301","article-title":"Alopecia areata in severe atopic dermatitis treated with dupilumab","volume":"28","author":"Barroso-Garc\u00eda","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.017_bib56","first-page":"e41","article-title":"Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect?","volume":"44","author":"Salg\u00fcero-Fern\u00e1ndez","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2021.06.017_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","article-title":"Drug-induced alopecia after dupilumab therapy","volume":"5","author":"Flanagan","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/DER.0000000000000458","article-title":"Alopecia areata after treatment with dupilumab","volume":"30","author":"Yazdanyar","year":"2019","journal-title":"Dermatitis"},{"issue":"8","key":"10.1016\/j.jaad.2021.06.017_bib59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","article-title":"Alopecia areata in 2 patients treated with dupilumab: new onset and worsening","volume":"5","author":"Chung","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib60","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/jdv.16782","article-title":"Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema","volume":"35","author":"Treudler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.017_bib62","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/DER.0000000000000651","article-title":"Acute pancreatitis in 2 adolescent boys on dupilumab therapy for atopic dermatitis","volume":"32","author":"Stoner","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2021.06.017_bib63","first-page":"1","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","author":"Lee","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2021.06.017_bib64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.017_bib65","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2019.10.015","article-title":"Dupilumab-induced bilateral cicatricial ectropion in real life","volume":"8","author":"Nettis","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2021.06.017_bib66","first-page":"275","article-title":"Dupilumab induced limbal stem cell deficiency","volume":"14","author":"Mehta","year":"2021","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.jaad.2021.06.017_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijwd.2021.04.004","article-title":"A clinician\u2019s guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults","author":"Semaan","year":"2021","journal-title":"Int J Womens Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221011191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221011191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:02:32Z","timestamp":1759273352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221011191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0190962221011191"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.06.017","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}